Abstract: Disclosed are methods for assessing the risk that a male subject is affected by prostate cancer and to methods for assessing the risk that such cancer is aggressive, by analysing the gaseous headspace of urine samples with at least three metal oxide semiconductor-based gas sensors, wherein the metal oxide of the first gas sensor is pure or doped SnO2, the metal oxide of the second sensor is pure or doped ZnO and the metal oxides of the third sensor are pure or doped SnO2, pure or doped TiO2 and pure or doped Nb2O5.

Abstract: The present invention provides antigen presenting cells (APC) carrying human tumor-associated peptides on the cell surface as well as immunogenic compositions including the tumor-associated peptides and/or the antigen presenting cells according to the invention. The immunogenic composition of the invention is useful as a vaccine in the prevention and/or treatment of a tumor disease, particularly melanoma and melanoma residual disease.

Abstract: The present invention refers to an in-vitro or ex vivo method for the prognosis of a Coronavirus disease and/or for the monitoring of the efficacy of a therapeutic treatment of a Coronavirus disease having the steps of: a) detecting and/or measuring the amount of the protein PTX3 or of fragments thereof or of the polynucleotide coding for the protein or of fragments thereof in an isolated biological sample obtained from the subject Preferably the method further includes—the step: b) comparing the same with a proper control.

Abstract: This invention pertains to a fluorescence lifetime imaging microscopy (FLIM)-based method for the quantitative three-dimensional (3D) imaging of the metabolic status of a lesion, including the acquisition of FLIM data of a least one anaerobic glycolysis marker. This method applies in particular to lesions such as wounds and tumours, and to markers such as the NADH/NAD+ ratio, the NAD(P)H/NAD+ ratio, the NADH/FAD ratio, the NAD(P)H/FAD ratio or the FADH/FAD ratio as a first marker, and their optional combination with a second marker such as pH, oxygen tension, glucose, pyruvate and lactate.

Abstract: The present invention relates to the use of inhibitors of T cell costimulation and/or activation and/or function in the treatment and/or prevention of cardiac pathologies, in particular heart failure diseases, and/or of related symptoms.

Abstract: The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.

Abstract: The present invention concerns a method for determining if a subject is affected by a colorectal or pancreatic cancer or for determining the stage and/or the progression of a colorectal cancer. By measuring the presence of a panel of m RNAs encoding for transcription factors/genes involved in epithelial to mesenchymal transition in a blood sample, wherein different mRNA levels of a set of genes comprising TWIST1, SLUG, ZEB2, ZEB1 and CDH1, are indicative of colorectal cancer or pancreatic cancer diagnosis, and/or of colorectal cancer stage at diagnosis, and/or of CRC metastatic progression after surgery. The invention concerns also the use of kits to work the method.

Abstract: The present invention refers to a stably or transiently IL-1R8 deficient isolated human cell, being a natural killer (NK) cell or T cell and to their medical use, preferably in the treatment of tumours and infections.

Abstract: The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.

Abstract: The present invention relates to the use of inhibitors of T cell costimulation and/or activation and/or function in the treatment and/or prevention of cardiac pathologies, in particular heart failure diseases, and/or of related symptoms.

Abstract: The present invention relates to a diagnostic test for inflammatory endothelial dysfunctions in pregnant women. Particularly, the present invention relates to a method of diagnosing or evaluating the risk of contracting an inflammatory endothelial dysfunction of the maternal compartment comprising the following steps: a) detecting the plasma levels of long pentraxin PTX3 in blood samples taken from a pregnant woman; b) comparing the PTX3 plasma level data, obtained according to step a), with statistically significant PTX3 plasma level data of normal pregnant population.

Abstract: Water soluble compounds having a furoxan structure which are capable of inhibiting metabolic pathways involved in the development of the tumours are provided. The use of such compounds as a medicament in the therapy of the tumours and as an adjuvant in the immunotherapy protocols against neoplasms is also described.

Abstract: The present invention relates to nitric oxide furoxan derivative compounds which showed to be active in the treatment of tumors. In addition, they may be used as adjuvants in cancer immunotherapy.

Abstract: The present invention relates to a method and an apparatus for processing and metrically quantifying images of objects containing clusters of points/spots, such as biological specimens comprising cluster of cells, in particular of human or animal origin, or images thereof.

Abstract: Water soluble compounds having a furoxan structure which are capable of inhibiting metabolic pathways involved in the development of the tumours are provided. The use of such compounds as a medicament in the therapy of the tumours and as an adjuvant in the immunotherapy protocols against neoplasms is also described.

Abstract: The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample.

Abstract: The present invention relates to an “in vitro” diagnostic method for diseases affecting human or animal tissues, in particular for the diagnosis of diseases involving inflammation and fibrosis in human or animals, more particularly for liver diseases.

Abstract: The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins.

Abstract: The present invention relates to a method and an apparatus for processing images of irregularly shaped objects, such as biological specimens, in particular of human or animal origin, or images thereof. The metric quantification of a biological body part or tissue or of an abnormal material spot or aggregate contained therein is also performed by means of the invention method. In particular, the present invention relates to a method for processing images of irregularly shaped objects, comprising a stage of acquisition of a digital image of said object, a stage of image elaboration (IMAEL) for quantifying said digital image to 1 bit and a stage of metrical processing of said 1-bit quantized image, wherein said stage of metrical processing comprises: —) a stage of object's metrical quantification (QUANT) for determining Euclidean perimeter P and/or area A of said object; —) a stage of dimensional calculation (DIM-CLC) for calculating a fractal-corrected perimeter Pf and/or area Af of said object.

Abstract: The present invention relates to an “in vitro” diagnostic method for diseases affecting human or animal tissues, in particular for the diagnosis of diseases involving inflammation and fibrosis in human or animals, more particularly for liver diseases.